The effect of nettle extract in patients with inflammatory bowel Disease

The effect of urtica dioica leaf extract on tumor necrosis factor alpha, high- sensitivity C- reactive protein, superoxide dismutase, erythrocyte sedimentation rate, blood cell count, calprotectin and quality of life in patient with inflammatory bowel disease compared with the control group that received placebo

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201410062709N30

Enrollment

Registered

2014-11-15

Start date

2014-11-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease. Crohn disease of small intestine, Ulcerative colitis

Interventions

Intervention 1: Stinging nettle tablet, produced in the company of barijessence, 400 mg tablet, three times a day for 3 months in intervention group. Intervention 2: Placebo, tablets containing starch

Treatment - Drugs

Placebo

Stinging nettle tablet, produced in the company of barijessence, 400 mg tablet, three times a day for 3 months in intervention group

Placebo, tablets containing starch, produced in Tehran University of Medical Sciences, 400 mg tablet, three times a day for 3 months in control group.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Willingness to participate in the study, inflammatory bowel disease in mild and moderate stages, no change in the type and dose of medication during the study, without any other diseases such as intestinal diseases, known autoimmune diseases, cancer, inflammatory diseases, infectious diseases, non-pregnant or breastfeeding women or non-use of contraceptive pill, not Having edema caused by heart or renal disease, no use of dietary supplements and herbal pills, no use of anticoagulant drugs such as heparin and antibiotics, patients in the study use similar types of drugs. Exclusion criteria: The patient's unwillingness to cooperate, exacerbation of disease resulting in hospitalization, changes in dosage and type of medication during intervention, sensitivity to nettle, compliance rate of less than 90%.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Erythrocyte Sedimentation Rate. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Automation Method (mm/h).;High- sensitivity C- reactive protein. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is mg/dl.;Quality of life. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Inflammatory Bowel Disease Questionnaire-Short Form.;White blood cell. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Flow cytometry Method (cells/ml).;Superoxide dismutase. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is ng/ml.;Platelet. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Flow cytometry Method (cells/µl).;Fecal calprotectin. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is µg/g.;Tumor necrosis factor alpha. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is ng/ml.	—

Measure

Time frame

Erythrocyte Sedimentation Rate. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Automation Method (mm/h).;High- sensitivity C- reactive protein. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is mg/dl.;Quality of life. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Inflammatory Bowel Disease Questionnaire-Short Form.;White blood cell. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Flow cytometry Method (cells/ml).;Superoxide dismutase. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is ng/ml.;Platelet. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: Flow cytometry Method (cells/µl).;Fecal calprotectin. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is µg/g.;Tumor necrosis factor alpha. Timepoint: At the Beginning of intervention and 3 months after Beginning of the intervention. Method of measurement: It is measured by kit (ELISA methods) and the unit is ng/ml.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Farzad Shidfar

Iran University of Medical Sciences

shidfar.f@iums.ac.ir+98 21 8862 2706

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026